Phase III Tracleerâ„¢ (bosentan) Study in Chronic Heart Failure

Document Sample
Phase III Tracleerâ„¢ (bosentan) Study in Chronic Heart Failure Powered By Docstoc
					Genentech, Inc.




Media Release
                                                                            7 February 2002


Phase III Tracleer™ (bosentan) Study in Chronic Heart
Failure Does Not Meet Primary Efficacy Objective
Long-term data confirms safety profile observed in earlier Pulmonary Arterial
Hypertension trials


ALLSCHWIL, SWITZERLAND and SOUTH SAN FRANCISCO– 7 February 2002:
Actelion Ltd (SWX New Market: ATLN) and Genentech, Inc. (NYSE: DNA) today
announced the Phase III ENABLE program evaluating endothelin receptor antagonist
Tracleer (bosentan) in 1,613 patients with severe chronic heart failure (CHF NYHA
Class IIIb/IV) did not reach statistical significance in the two pre-defined primary
endpoints: risk reduction in time to death or hospitalization due to CHF, and improvement
in clinical status at nine months of treatment.


Isaac Kobrin, Head of Clinical Development at Actelion, commented: "Though we did not
see efficacy in CHF for Tracleer™, the ENABLE trial did importantly generate long-term
data about safety in patients receiving Tracleer™ for up to 30 months, confirming the
same safety profile as observed in earlier clinical trials. This is an important finding for
Tracleer’s™ first approved indication Pulmonary Arterial Hypertension. We are
encouraged by this safety finding in a larger patient population and will further evaluate
the use of Tracleer™ in other indications. Actelion is in the process of preparing new
clinical trial programs for Tracleer™.”


Under an agreement concluded in December 2000, in certain circumstances Genentech
has the opportunity to become a co-promotion partner for Tracleer. An option was
exercisable if the ENABLE study reached statistical significance for the primary endpoints.
Based on the ENABLE results, Genentech cannot exercise this option but can explore
other opportunities under the current agreement.
                                                                                                        Page 2



The full findings of the ENABLE trial, including subgroup analyses, will be presented at the
American College of Cardiology meeting, March 17-21, in Atlanta.


Tracleer™ is currently available in the United States as a treatment for pulmonary arterial
hypertension. The drug was approved for this indication by the U.S. Food and Drug
Administration on Nov. 20, 2001, and is currently marketed by Actelion Pharmaceuticals
US. The drug is also available in Canada and currently under regulatory review in the
European Union, Switzerland and Australia.


                                                      ###


Genentech, Inc.
Genentech, Inc., is a leading biotechnology company that discovers, develops, manufactures and markets
human pharmaceuticals for significant unmet medical needs. Fifteen of the currently approved products of
biotechnology are based on or stem from Genentech science. Genentech markets ten products directly in the
United States. The company has headquarters in South San Francisco, California and is traded on the New
York Stock Exchange under the symbol DNA.


Actelion Ltd
Actelion Ltd is a biopharmaceutical company headquartered in Allschwil/Basel Switzerland and has a
substantial US operation based in South San Francisco. Actelion is a leading player in innovative science
related to the endothelium – the single layer of cells separating every blood vessel from the blood stream.
Actelion focuses on the discovery, development and marketing of innovative drugs for significant unmet
medical needs. Actelion shares are traded on the Swiss Stock Exchange (SWX New Market ATLN).



Media/Investor Contacts             Roland Haefeli              Actelion          +41 61 487 34 58
Media Contacts:                     Shelley Schneiderman Genentech                +1 650 225 78 48
Investor Contact:                   Katherine Littrell          Genentech         +1 650 225 10 34
http://www.actelion.com
http://www.gene.com
Invitation to
Investor
Conference
Call


Phase III Tracleer™ (bosentan) Study in Chronic Heart Failure Does
Not Meet Primary Efficacy Objective
Long-term data confirms safety profile observed in earlier Pulmonary Arterial
Hypertension trials

                                                                                    7 February 2002
Dear Friend in the Investment Community

Actelion Ltd today announced on Thursday, 7 February 2002, that the Phase III ENABLE
program evaluating the endothelin receptor antagonist TracleerTM (bosentan) in patients with
severe chronic heart failure did not reach statistical significance in the two pre-defined
primary efficacy endpoints. The study importantly generated long-term data confirming the
safety profile observed in earlier Pulmonary Arterial Hypertension trials.

Actelion will host an Investor Conference Call and discussion/Q&A as follows:

Date/Time:      Thursday, 7 February 2002, 07.45 (CET)

Conference
Connect #:      +41 (0) 848 22 41 11 – (Europe). Dial-in participants should start calling the above number
                15-10 minutes before the Conference is due to start.
                (U.S. participants should dial +1 412 858 46 00)
                Emergency number in case of difficulties/questions +41 (0) 91 610 24 75


Participant’s
mode:           Listen-Only, with possibility to open individual lines during Q&A session. Participants
                will be asked for their Name and Company.
                The conference will be held in English.
There will be a Digital Playback for 48 hours after the call, commencing at 10.00 CET.
Participants wishing to listen to the Digital Playback should dial:
        Europe         +41 (0) 848 72 25 00
        U.S.           +1 412 858 14 40
        Conference PIN Code 329#

Sincerely yours,
Roland Haefeli, Head of Corporate Communications/Investor Relations

				
DOCUMENT INFO
Shared By:
Categories:
Stats:
views:6
posted:8/31/2010
language:English
pages:3